| Drug Name | TECFIDERA (DIMETHYL FUMARATE) |
|---|---|
| Drug Class | |
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Neurology
|
| Risk |
Updated recommendations in the light of cases of progressive multifocal leukoencephalopathy (PML) in the setting of mild lymphopenia. |
| Dear Healthcare provider letter DHPC |
|